Search - tctmd.com

Displaying 141 - 160 of 188

Sort: Relevancy | Date

Presentation TCT 2015

Debulking in the Antiproliferative Era: Which Patient Is Most Likely to Benefit?

Presenter: Prakash Krishnan, Mahmood K. Razavi, Lawrence A. Garcia

October 11, 2015

Presentation TCT 2015

A Master Class in Atherectomy: Choices, Strategies, and Execution

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Presenter: Prakash Krishnan, Mahmood K. Razavi, Christopher D. Owens

October 11, 2015

Presentation TCT 2015

Update on Bioresorbable Scaffolds for PAD

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Presenter: Gary M. Ansel, Michael R. Jaff, John R. Laird Jr

October 11, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Presentation TCT 2015

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Presenter: Gary M. Ansel, Michael R. Jaff, William A. Gray

October 11, 2015

Presentation TCT 2015

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

Presenter: Gary M. Ansel, Michael R. Jaff, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Presenter: Julie Logan, George L Adams

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Presenter: Julie Logan, William A. Gray

October 11, 2015

News Features TCT 2014

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Todd Neale

October 31, 2014

Presentation TCT 2014

Tissue Removal Assessment with Ultrasound of the SFA and Popliteal Study (TRUTH): Orbital Atherectomy Acute Data and Intravascular Ultrasound Analysis

Presenter: Anvar Babaev

September 16, 2014

Presentation TCT 2014

TCT 269: Drug-Coated Balloon vs Standard Balloon for the PTA Treatment of Lesions in the SFA and Popliteal Artery? First Interim Results of the FREERIDE Study

Presenter: Peter A. Schneider, Gunnar Tepe, Michael H. Wholey, Schulte Karl-Ludwig, MD

September 15, 2014

Presentation TCT 2014

TCT 532: Economic Outcomes of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons vs Standard PTA: 1-Year Results from the IN.PACT SFA II Trial

Presenter: Peter A. Schneider, Gunnar Tepe, Michael H. Wholey, Adam Salisbury, MD

September 15, 2014

Presentation TCT 2014

Randomized Controlled Trials I: New Insights From INPACT SFA II

Presenter: Kenneth Rosenfield, Thomas Zeller, Raghu Kolluri, John R. Laird Jr

September 15, 2014

Presentation TCT 2014

Master Class in SFA Technologies: Lining up the Data

Presenter: Robert M. Bersin, Dierk Scheinert, Roger Gammon, William A. Gray

September 13, 2014

Advertisement

Debulking in the Antiproliferative Era: Which Patient Is Most Likely to Benefit?

A Master Class in Atherectomy: Choices, Strategies, and Execution

Biomimetic Stents: Rationale and Current Clinical Results

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Update on Bioresorbable Scaffolds for PAD

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Tissue Removal Assessment with Ultrasound of the SFA and Popliteal Study (TRUTH): Orbital Atherectomy Acute Data and Intravascular Ultrasound Analysis

TCT 269: Drug-Coated Balloon vs Standard Balloon for the PTA Treatment of Lesions in the SFA and Popliteal Artery? First Interim Results of the FREERIDE Study

TCT 532: Economic Outcomes of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons vs Standard PTA: 1-Year Results from the IN.PACT SFA II Trial

Randomized Controlled Trials I: New Insights From INPACT SFA II

Master Class in SFA Technologies: Lining up the Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content